Catalyst Biosciences Total Revenue

As of the most recent data (June 2026), CBIO shows a total revenue of $-30M. That compares with $150M in the prior-year period — down 119.3% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CBIO's total revenue is now $-30M (was $150M) — a 119.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Catalyst Biosciences is outperforming or lagging.

The Healthcare sector average total revenue is about $110B. Catalyst Biosciences is at $-30M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CBIO stacks up against individual peers as well.

Tracking CBIO's total revenue over time shows whether Catalyst Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-30M That compares with $150M in the prior-year period — down 119.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Catalyst Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $-30M) with ownership activity and broader fundamentals.